Literature DB >> 15109536

Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients.

Sara Galimberti1, Francesca Guerrini, Giuseppe Alberto Palumbo, Ugo Consoli, Rita Fazzi, Fortunato Morabito, Valeria Santini, Mario Petrini.   

Abstract

Expression of two MDR genes, BCRP and MDR1, was evaluated by real-time PCR technique in 51 AML patients. Fifty-six percent expressed the BCRP gene, with the 48.2% showing intermediate levels. Eighty-eight percent expressed the MDR1, with 23.8% of cases at high expression. A significant correlation between BCRP and MDR1 values was found by regression analysis. Either levels of BCRP or MDR1 did not correlate with clinical characteristics of patients at diagnosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15109536     DOI: 10.1016/j.leukres.2003.09.002

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  11 in total

Review 1.  The controversial role of ABC transporters in clinical oncology.

Authors:  Akina Tamaki; Caterina Ierano; Gergely Szakacs; Robert W Robey; Susan E Bates
Journal:  Essays Biochem       Date:  2011-09-07       Impact factor: 8.000

2.  Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo.

Authors:  Kamlesh Sodani; Atish Patel; Nagaraju Anreddy; Satyakam Singh; Dong-Hua Yang; Rishil J Kathawala; Priyank Kumar; Tanaji T Talele; Zhe-Sheng Chen
Journal:  Biochem Pharmacol       Date:  2014-02-22       Impact factor: 5.858

Review 3.  Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

Authors:  Karthika Natarajan; Yi Xie; Maria R Baer; Douglas D Ross
Journal:  Biochem Pharmacol       Date:  2012-01-11       Impact factor: 5.858

4.  Human ABCG2: structure, function, and its role in multidrug resistance.

Authors:  Wei Mo; Jian-Ting Zhang
Journal:  Int J Biochem Mol Biol       Date:  2011-03-30

Review 5.  The challenge of exploiting ABCG2 in the clinic.

Authors:  Robert W Robey; Caterina Ierano; Zhirong Zhan; Susan E Bates
Journal:  Curr Pharm Biotechnol       Date:  2011-04       Impact factor: 2.837

6.  Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.

Authors:  Carla S Wilson; George S Davidson; Shawn B Martin; Erik Andries; Jeffrey Potter; Richard Harvey; Kerem Ar; Yuexian Xu; Kenneth J Kopecky; Donna P Ankerst; Holly Gundacker; Marilyn L Slovak; Monica Mosquera-Caro; I-Ming Chen; Derek L Stirewalt; Maurice Murphy; Frederick A Schultz; Huining Kang; Xuefei Wang; Jerald P Radich; Frederick R Appelbaum; Susan R Atlas; John Godwin; Cheryl L Willman
Journal:  Blood       Date:  2006-04-04       Impact factor: 22.113

7.  Does aberrant membrane transport contribute to poor outcome in adult acute myeloid leukemia?

Authors:  Alexandre Chigaev
Journal:  Front Pharmacol       Date:  2015-07-02       Impact factor: 5.810

8.  Possible Role of microRNA-122 in Modulating Multidrug Resistance of Hepatocellular Carcinoma.

Authors:  Shaymaa M M Yahya; Shadia A Fathy; Zakaria A El-Khayat; Safinaz E El-Toukhy; Ahmed R Hamed; Marwa G A Hegazy; Heba K Nabih
Journal:  Indian J Clin Biochem       Date:  2017-04-21

Review 9.  Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.

Authors:  Takeo Nakanishi; Douglas D Ross
Journal:  Chin J Cancer       Date:  2011-11-18

10.  A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo.

Authors:  Nagaraju Anreddy; Atish Patel; Yun-Kai Zhang; Yi-Jun Wang; Suneet Shukla; Rishil J Kathawala; Priyank Kumar; Pranav Gupta; Suresh V Ambudkar; John N D Wurpel; Zhe-Sheng Chen; Huiqin Guo
Journal:  Oncotarget       Date:  2015-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.